Product NDC: | 16729-079 |
Proprietary Name: | CARBIDOPA AND LEVODOPA |
Non Proprietary Name: | Carbidopa and Levodopa |
Active Ingredient(s): | 50; 200 mg/1; mg/1 & nbsp; Carbidopa and Levodopa |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, EXTENDED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 16729-079 |
Labeler Name: | Accord Healthcare, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA202323 |
Marketing Category: | ANDA |
Start Marketing Date: | 20130509 |
Package NDC: | 16729-079-01 |
Package Description: | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-079-01) |
NDC Code | 16729-079-01 |
Proprietary Name | CARBIDOPA AND LEVODOPA |
Package Description | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-079-01) |
Product NDC | 16729-079 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Carbidopa and Levodopa |
Dosage Form Name | TABLET, EXTENDED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20130509 |
Marketing Category Name | ANDA |
Labeler Name | Accord Healthcare, Inc. |
Substance Name | CARBIDOPA; LEVODOPA |
Strength Number | 50; 200 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA] |